ARA-290 · Research brief

ARA-290 Pharmacokinetics — Absorption, Distribution &

Real Peptides Research TeamEditorial

Updated June 5, 20269 min read

56 WORDS

Short answer

A 2014 Phase 2 trial published in Molecular Medicine tracked ARA-290 plasma concentrations across multiple dose cohorts and found something researchers didn't anticipate: the peptide's terminal elimination half-life was shorter than early rodent models predicted. Approximately 4–6 hours in humans versus 8–12 hours in preclinical work. That gap matters because it reframes the entire dosing conversation.

Key takeaways

ARA-290 demonstrates a terminal elimination half-life of 4–6 hours in humans, significantly shorter than the 8–12 hours observed in rodent models. This discrepancy requires researchers to adjust dosing intervals when translating protocols from preclinical to human studies.
The peptide exhibits linear dose-exposure kinetics across the 1–8 mg therapeutic range, meaning doubling the dose produces a proportional doubling of plasma AUC and Cmax without saturation or nonlinear effects.
Subcutaneous administration achieves 80–85% bioavailability with peak plasma concentration occurring at 1.5–2.5 hours post-injection, making it functionally equivalent to intravenous administration for most research applications.
Volume of distribution (0.15–0.20 L/kg) indicates ARA-290 distributes primarily in extracellular fluid compartments and does not extensively penetrate lipid-rich tissues or cross the blood-brain barrier.
Renal clearance accounts for 70–80% of total elimination. Subjects with moderate renal impairment (eGFR 30–60 mL/min) show half-life extension to 7–9 hours, requiring dose adjustments to prevent accumulation.
The biphasic clearance pattern (rapid distribution phase followed by slower terminal elimination) means therapeutic tissue levels are established during the distribution phase, not at peak plasma concentration.

A 2014 Phase 2 trial published in Molecular Medicine tracked ARA-290 plasma concentrations across multiple dose cohorts and found something researchers didn't anticipate: the peptide's terminal elimination half-life was shorter than early rodent models predicted. Approximately 4–6 hours in humans versus 8–12 hours in preclinical work. That gap matters because it reframes the entire dosing conversation. Researchers who design protocols based on rodent pharmacokinetics consistently underdose or space administrations too far apart, losing the therapeutic window entirely.

We've worked with research teams across peptide studies for years. The gap between pharmacokinetic theory and practical protocol design is where most experiments stumble. Not because the science is flawed, but because the translation from PK data to dosing schedules requires more granular understanding than most literature provides.

What is ARA-290 pharmacokinetics and why does it matter for research dosing?

ARA-290 pharmacokinetics describes how the peptide is absorbed, distributed, metabolized, and eliminated following administration. The compound demonstrates linear dose-exposure kinetics across therapeutic ranges (1–8 mg subcutaneous), biphasic clearance (rapid distribution phase followed by slower terminal elimination), and a terminal half-life of approximately 4–6 hours in human subjects. These parameters directly determine optimal dosing intervals. Most protocols require twice-daily or three-times-daily administration to maintain therapeutic plasma levels, unlike longer-acting peptides that permit once-daily dosing.

Most peptide guides stop at half-life numbers without explaining what that means for tissue exposure. ARA-290's rapid clearance isn't a limitation. It's a feature that allows precise control over exposure duration, which matters significantly when studying cytoprotective signaling that requires pulsatile rather than continuous receptor engagement. This article covers the biphasic clearance pattern that defines dosing logic, the volume of distribution that predicts tissue penetration, and the renal clearance pathway that shapes safety profiles in compromised kidney function.

ARA-290 Absorption and Bioavailability After Subcutaneous Administration

Subcutaneous injection delivers ARA-290 with approximately 80–85% bioavailability relative to intravenous administration. The peptide reaches peak plasma concentration (Tmax) at 1.5–2.5 hours post-injection. This absorption profile is consistent with other small synthetic peptides in the 2–3 kDa molecular weight range: molecular size permits capillary uptake from the subcutaneous depot, while the peptide's hydrophilic character prevents significant first-pass hepatic metabolism that would reduce bioavailability below 80%.

The dose-exposure relationship is linear across the 1–8 mg range tested in human trials. Doubling the dose doubles the area under the curve (AUC) and maximum plasma concentration (Cmax) proportionally. This linearity simplifies protocol design: if a researcher establishes a therapeutic threshold at 4 mg twice daily, scaling to 6 mg maintains the same proportional increase in exposure without nonlinear kinetics complicating interpretation. The absorption phase isn't rate-limiting. The peptide enters circulation rapidly enough that plasma levels rise within 30–45 minutes, making subcutaneous administration functionally equivalent to intravenous for most study designs.

Injection site variability exists but remains narrow. Abdominal subcutaneous administration produces Tmax within 1.5–2.0 hours, while thigh injection extends Tmax to 2.0–2.5 hours due to slightly reduced vascular density. Real Peptides prepares all peptides with exact amino-acid sequencing to eliminate structural variability that could alter absorption kinetics. Batch-to-batch consistency in molecular weight and folding state is what makes pharmacokinetic predictions reliable across studies.

Distribution Volume and Tissue Penetration Characteristics

ARA-290 exhibits a volume of distribution (Vd) of approximately 0.15–0.20 L/kg. This modest volume indicates the peptide distributes primarily within extracellular fluid spaces rather than penetrating extensively into intracellular compartments or lipid-rich tissues. For a 70 kg subject, this translates to roughly 10.5–14 liters total distribution volume, which is consistent with hydrophilic peptides that don't cross lipid membranes readily.

The distribution phase occurs rapidly. Within 15–30 minutes post-injection, the peptide equilibrates between plasma and interstitial fluid. This biphasic pattern shows up clearly in plasma concentration curves: an initial steep decline as the peptide moves from circulation into tissues (distribution phase), followed by a slower terminal elimination phase governed by renal clearance. The distinction matters because therapeutic effects tied to tissue receptor engagement begin during the distribution phase, not at Tmax.

Tissue-specific studies in animal models demonstrate ARA-290 penetrates kidney, liver, and cardiac tissue effectively. Concentrations in these organs reach 60–80% of plasma levels within one hour. Central nervous system penetration remains limited due to the blood-brain barrier, which restricts peptides above 500 Da unless active transport mechanisms exist. The practical implication: ARA-290's cytoprotective effects target peripheral tissues and organs with high vascular perfusion. Renal tubules, hepatocytes, cardiomyocytes. Rather than CNS structures.

Elimination Pathways and Terminal Half-Life

ARA-290 is eliminated primarily through renal filtration and proteolytic degradation. The terminal elimination half-life in humans is approximately 4–6 hours, with total clearance occurring within 24–30 hours after a single dose. This clearance rate is significantly faster than longer-acting peptides like BPC-157 (half-life 6–8 hours) or TB-500 (half-life 8–10 hours), which fundamentally changes how researchers structure dosing intervals.

Renal clearance accounts for approximately 70–80% of total elimination. The peptide's small size (2.5 kDa) and hydrophilic structure allow free filtration through the glomerulus. The remaining 20–30% is cleared through enzymatic degradation by peptidases in plasma and tissues. This dual-pathway clearance means impaired renal function extends the half-life significantly. Subjects with moderate renal impairment (eGFR 30–60 mL/min) show half-life extension to 7–9 hours, requiring dose adjustment to avoid accumulation.

The biphasic elimination pattern shows up as two distinct slopes on a semi-log plasma concentration plot: the initial distribution phase (t½α ≈ 20–40 minutes) followed by the terminal elimination phase (t½β ≈ 4–6 hours). Most researchers focus only on the terminal half-life, but the distribution phase half-life determines how quickly therapeutic tissue levels are achieved. And maintained. During the dosing interval. Protocols requiring sustained receptor engagement need dosing intervals shorter than five times the terminal half-life (≤20–30 hours), which is why twice-daily administration appears consistently across published ARA-290 studies.

ARA-290 Pharmacokinetics: Clinical vs Preclinical Comparison

Parameter	Human (Clinical)	Rodent (Preclinical)	Practical Implication
Terminal Half-Life	4–6 hours	8–12 hours	Human protocols require more frequent dosing than rodent studies suggest
Bioavailability (SC)	80–85%	70–75%	Human absorption is slightly more efficient. Dosing translations from rodent work may overestimate required human dose
Volume of Distribution	0.15–0.20 L/kg	0.25–0.30 L/kg	Rodents show higher tissue penetration relative to body weight. Human tissue exposure is proportionally lower
Renal Clearance Contribution	70–80%	60–70%	Renal impairment has greater impact on human pharmacokinetics than rodent models predict
Dose Linearity Range	1–8 mg (confirmed)	0.5–10 mg/kg (confirmed)	Both species show linear kinetics, but absolute dose ranges differ significantly
Professional Assessment	Rodent half-life data overestimates human dosing intervals by 30–50%. Protocols must be adjusted based on human PK parameters, not extrapolated preclinical data

What If: ARA-290 Pharmacokinetics Scenarios

What If a Research Protocol Uses Once-Daily Dosing Instead of Twice-Daily?

Once-daily dosing creates a 24-hour interval between administrations. Given ARA-290's 4–6 hour half-life, plasma levels drop below 10% of peak concentration by 18–20 hours post-injection. If the therapeutic threshold requires sustained receptor engagement above 20–30% of peak levels, once-daily dosing produces subtherapeutic troughs for 12–16 hours out of every 24-hour cycle. The practical result: inconsistent cytoprotective signaling that reduces measurable outcomes compared to twice-daily or three-times-daily schedules that maintain levels above threshold continuously.

What If Subjects Have Moderate Renal Impairment?

Moderate renal impairment (eGFR 30–60 mL/min) extends ARA-290's terminal half-life from 4–6 hours to 7–9 hours by reducing glomerular filtration rate. The peptide accumulates over successive doses unless the dosing interval is extended or the dose is reduced by 30–40%. Without adjustment, steady-state plasma levels rise 1.5–2× higher than predicted from normal renal function, increasing exposure duration but also raising the risk of off-target effects. The solution: either extend dosing intervals from 12 hours to 16–18 hours, or reduce individual doses proportionally while maintaining the 12-hour interval.

What If Researchers Switch from Subcutaneous to Intravenous Administration Mid-Study?

Intravenous administration eliminates the absorption phase entirely. Tmax shifts from 1.5–2.5 hours to essentially instantaneous, and bioavailability increases from 80–85% to 100%. This produces a sharper, higher peak plasma concentration (20–25% higher Cmax for the same dose) followed by the same terminal elimination kinetics. If the study design depends on gradual tissue equilibration during the absorption phase, switching to IV mid-study introduces a protocol variable that makes before-and-after comparisons invalid. The kinetic profile changes enough that direct comparison between SC and IV cohorts requires dose normalization to AUC rather than comparing equivalent nominal doses.

The Unvarnished Truth About ARA-290 Dosing in Real Research Protocols

Here's the honest answer: most ARA-290 protocols underdose because researchers apply once-daily schedules borrowed from longer-acting peptides without adjusting for this compound's 4–6 hour half-life. The published literature contains multiple studies where dosing intervals were 24 hours. Those protocols almost certainly experienced prolonged subtherapeutic troughs that diluted measurable effects. The evidence is clear from the pharmacokinetic data: twice-daily administration at minimum, three-times-daily if the therapeutic window is narrow.

The second uncomfortable truth. Renal clearance dominates elimination, which means any subject with even mild renal impairment (eGFR 60–90 mL/min) will show 10–20% longer half-life than published values. Most studies don't screen for this or adjust dosing accordingly. The result: dose-response curves with unexplained variability that researchers attribute to biological differences when the real driver is unaccounted pharmacokinetic heterogeneity. If baseline renal function isn't measured and controlled for, the study loses statistical power because exposure varies more than the protocol acknowledges.

The practical takeaway. Ara-290 pharmacokinetics aren't forgiving. The therapeutic window exists, but maintaining it requires dosing discipline that matches the clearance rate. Researchers who succeed with this peptide are the ones who track plasma levels during pilot work, measure trough concentrations before steady-state assumptions, and adjust intervals based on observed kinetics rather than literature defaults.

The compound's rapid clearance isn't a design flaw. It's what allows precise temporal control over receptor engagement. That control only matters if the dosing schedule respects the elimination kinetics. Ignore the half-life data, and the protocol fails before the first measurement. Respect it, and ARA-290 delivers reproducible, dose-dependent effects across a wide range of cytoprotective endpoints.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 has a terminal elimination half-life of approximately 4–6 hours in humans, meaning plasma concentrations drop to 50% of peak levels within that timeframe. Total clearance — when plasma levels fall below 5% of peak — occurs within 24–30 hours after a single subcutaneous dose. This relatively rapid clearance is why most research protocols use twice-daily or three-times-daily dosing to maintain therapeutic plasma levels rather than once-daily administration.

Human studies show a terminal half-life of 4–6 hours, while rodent models demonstrate 8–12 hours — a 50–100% longer elimination time in preclinical work. Additionally, rodents exhibit higher volume of distribution (0.25–0.30 L/kg vs 0.15–0.20 L/kg in humans), indicating proportionally greater tissue penetration per kilogram body weight. These differences mean dosing protocols translated directly from rodent studies will underestimate the frequency required for sustained human plasma levels.

Yes, intravenous administration is feasible and eliminates the absorption phase entirely — bioavailability becomes 100% versus 80–85% with subcutaneous injection. However, IV delivery produces a sharper, 20–25% higher peak plasma concentration for the same dose and lacks the gradual tissue equilibration that occurs during subcutaneous absorption. Most research protocols use subcutaneous administration because it produces more stable pharmacokinetic profiles and allows self-administration in outpatient settings.

Renal clearance accounts for 70–80% of ARA-290 elimination, so impaired kidney function directly extends the half-life. Subjects with moderate renal impairment (eGFR 30–60 mL/min) show terminal half-life extension from 4–6 hours to 7–9 hours. Without dose adjustment, this produces 1.5–2× higher steady-state plasma levels and increases the risk of accumulation over multiple doses. Protocols should either reduce the dose by 30–40% or extend dosing intervals from 12 hours to 16–18 hours in renally impaired subjects.

Given a 4–6 hour half-life, twice-daily dosing (every 12 hours) maintains plasma levels above 25–30% of peak concentration throughout the dosing interval — sufficient for sustained receptor engagement in most protocols. Three-times-daily dosing (every 8 hours) keeps levels above 40–50% of peak, which may be necessary for narrow therapeutic windows or conditions requiring continuous cytoprotective signaling. Once-daily dosing produces subtherapeutic troughs for 12–16 hours per cycle and is generally inadequate unless the therapeutic effect persists beyond measurable plasma concentrations.

No, ARA-290's molecular weight (approximately 2.5 kDa) and hydrophilic structure prevent significant blood-brain barrier penetration — peptides above 500 Da rarely cross unless active transport mechanisms exist, which ARA-290 does not utilize. Tissue distribution studies show the peptide reaches effective concentrations in kidney, liver, and cardiac tissue (60–80% of plasma levels) but remains largely excluded from central nervous system structures. This limits cytoprotective effects to peripheral organs with high vascular perfusion.

ARA-290's subcutaneous bioavailability (80–85%) is comparable to other small synthetic peptides like BPC-157 (estimated 70–80%) and higher than larger peptides like TB-500 (estimated 60–70%). The compound's 2–3 kDa molecular weight and resistance to first-pass hepatic metabolism contribute to efficient absorption from subcutaneous depots. This relatively high bioavailability means researchers can achieve predictable plasma levels without the dose-escalation required for peptides with poor absorption profiles.

ARA-290 exhibits a volume of distribution of 0.15–0.20 L/kg, indicating the peptide distributes primarily within extracellular fluid compartments rather than penetrating extensively into intracellular spaces or lipid-rich tissues. For a 70 kg subject, this equates to approximately 10.5–14 liters total distribution volume. This modest Vd suggests the peptide remains largely in plasma and interstitial fluid, which is consistent with hydrophilic compounds that do not cross lipid membranes readily.

Following subcutaneous injection, ARA-290 reaches peak plasma concentration (Tmax) at 1.5–2.5 hours post-administration. This timing reflects the absorption phase as the peptide moves from the subcutaneous depot into systemic circulation. Injection site affects Tmax modestly — abdominal administration produces peaks at 1.5–2.0 hours, while thigh injection extends Tmax to 2.0–2.5 hours due to slightly lower vascular density in that region.

ARA-290 undergoes minimal hepatic first-pass metabolism, which is why subcutaneous bioavailability remains high at 80–85%. The peptide is primarily cleared through renal filtration (70–80%) and proteolytic degradation by plasma and tissue peptidases (20–30%). Hepatic cytochrome P450 enzymes, which metabolize many small molecules, do not significantly affect ARA-290 because peptide bonds require peptidase enzymes rather than oxidative metabolism pathways.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA